Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03177798 · ClinicalTrials.gov registry record · Phase 2
Mitochondria and Chronic Kidney Disease
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT03177798 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 11 participants.
The verdict
NCT03177798, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The overarching goal of this study is to determine the role of chronic kidney disease and the activation of the kallikrein-kinin system during hemodialysis on the development of mitochondrial dysfunction; the investigators will measure mitochondrial function using the gold standard method, 31-phosphorus magnetic resonance spectroscopy. The investigators will test the hypothesis that endogenous bradykinin promotes mitochondrial dysfunction in patients undergoing hemodialysis. The investigators will first perform a randomized, placebo-controlled, double-blind, cross-over study measuring the effect of Icatibant (HOE-140), a bradykinin B2 receptor blocker, on mitochondrial function.
Interventions
- DRUG Placebo
- DRUG Icatibant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2018-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03177798
The ClinicalTrials.gov registry entry for NCT03177798 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03177798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03177798 about?
NCT03177798 is a clinical study titled "Mitochondria and Chronic Kidney Disease". The overarching goal of this study is to determine the role of chronic kidney disease and the activation of the kallikrein-kinin system during hemodialysis on the development of mitochondrial dysfunction; the investigators will measure mitochondrial function using the gold standard method, 31-phosph...
What is the current status of trial NCT03177798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2017-08-01. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT03177798?
The interventions under investigation include: Placebo (DRUG), Icatibant (DRUG).
Who is sponsoring clinical trial NCT03177798?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.